Last updated: 2026-09-06 05:40:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
MeiraGTx Holdings plc (MGTX) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $13.89, with a market capitalization of $1.35B and a P/E ratio of 16.99. Over the past 52 weeks, its price has ranged from $6.62 to $15.35. This page covers its latest market performance, valuation, price trends and company information.
$1.35B | |
$13.70 | |
$30.23 | |
$3.49 | |
$13.97 | |
386.50K | |
-- | |
16.99 | |
$15.35 | |
$6.62 | |
-- | |
-- |
MeiraGTx Holdings plc (MGTX) last closed at $13.97 as of 2026-09-04 23:31:00, unchanged from the previous close of $13.97.
During the latest regular trading session, MGTX traded between $3.49 and $30.23, with a volume of 386.50K shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, MeiraGTx Holdings plc (MGTX) moved from $13.90 to $13.89, representing a decline of 0.07% ($0.01).
The stock traded between $13.62 and $14.20 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 786.96 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 83.2%
MGTX is currently trading at $13.89, placing it 83.2% of the way from its 52-week low of $6.62 to its 52-week high of $15.35. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 393 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of MeiraGTx Holdings plc (MGTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.